• Home
  • Search Results
  • Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.

Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.

Fundamental & clinical pharmacology (2008-05-20)
S Budhiraja, J Singh
ABSTRACT

Diabetic nephropathy (DN) has emerged as the major causative pathology in patients entering end-stage renal disease (ESRD) worldwide and it is responsible for 30-40% of all ESRD cases. Treatments for DN are centered on control of hyperglycemia and blood pressure control. However, current therapeutic regimens have not yet provided satisfactory prevention from the onset of DN. Protein kinase C (PKC) is an intracellular signaling molecule and activation of it plays an important role in the development of diabetic complications. In numerous experimental and clinical studies, inhibition of PKC (LY333531) has been shown to delay/halt the progression of diabetic complications. Presently, the drug is submitted in USA-FDA for new drug application in moderate to severe diabetic retinopathy. This review selectively discusses the role of PKC in DN and therapeutic effects produced by PKC inhibitors in DN. The role of PKC inhibitor in other diabetic complications is also discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Protein Kinase Cα antibody produced in rabbit, whole antiserum
Sigma-Aldrich
Anti-Protein Kinase Cβ2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-Protein Kinase Cβ2 antibody produced in mouse, clone PK-B26, ascites fluid
Sigma-Aldrich
Anti-Protein Kinase Cβ2 antibody produced in rabbit, 0.5 mg/mL, affinity isolated antibody

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.